Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver

BMC Cancer

Alexandra Naba²  Karl R Clauser¹  Charles A Whittaker⁴  Steven A Carr¹  Kenneth K Tanabe³  Richard O Hynes² 

[1] Proteomics Platform, Broad Institute of MIT and Harvard, 02142 Cambridge, MA, USA

[2] Howard Hughes Medical Institute, Massachusetts Institute of Technology, 02139 Cambridge, MA, USA

[3] Division of Surgical Oncology, Massachusetts General Hospital Cancer Center, Boston 02114, MA, USA

[4] David H. Koch Institute for Integrative Cancer Research - Barbara K. Ostrom Bioinformatics and Computing facility at the Swanson Biotechnology Center, 02139 Cambridge, MA, USA

关键词: Matrisome;    Tumor microenvironment;    Metastasis;    Colorectal cancer;    Proteomics;    Extracellular matrix;   

Others  :  1125336
DOI  :  10.1186/1471-2407-14-518

 received in 2014-03-03, accepted in 2014-06-30,  发布年份 2014

【 摘 要 】

Background

Colorectal cancer is the third most frequently diagnosed cancer and the third cause of cancer deaths in the United States. Despite the fact that tumor cell-intrinsic mechanisms controlling colorectal carcinogenesis have been identified, novel prognostic and diagnostic tools as well as novel therapeutic strategies are still needed to monitor and target colon cancer progression. We and others have previously shown, using mouse models, that the extracellular matrix (ECM), a major component of the tumor microenvironment, is an important contributor to tumor progression. In order to identify candidate biomarkers, we sought to define ECM signatures of metastatic colorectal cancers and their metastases to the liver.

Methods

We have used enrichment of extracellular matrix (ECM) from human patient samples and proteomics to define the ECM composition of primary colon carcinomas and their metastases to liver in comparison with normal colon and liver samples.

Results

We show that robust signatures of ECM proteins characteristic of each tissue, normal and malignant, can be defined using relatively small samples from small numbers of patients. Comparisons with gene expression data from larger cohorts of patients confirm the association of subsets of the proteins identified by proteomic analysis with tumor progression and metastasis.

Conclusions

The ECM protein signatures of metastatic primary colon carcinomas and metastases to liver defined in this study, offer promise for development of diagnostic and prognostic signatures of metastatic potential of colon tumors. The ECM proteins defined here represent candidate serological or tissue biomarkers and potential targets for imaging of occult metastases and residual or recurrent tumors and conceivably for therapies. Furthermore, the methods described here can be applied to other tumor types and can be used to investigate other questions such as the role of ECM in resistance to therapy.

【 授权许可】

   
2014 Naba et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Rustgi AK: The genetics of hereditary colon cancer. Genes Dev 2007, 21:2525-2538.
• [2]Network CGA: Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
• [3]Hanash S, Taguchi A: The grand challenge to decipher the cancer proteome. Nat Rev Cancer 2010, 10:652-660.
• [4]De Wit M, Fijneman RJA, Verheul HMW, Meijer GA, Jimenez CR: Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications. Clin Biochem 2013, 46:466-479.
• [5]Luo Y, Wang L, Wang J: Developing proteomics-based biomarkers for colorectal neoplasms for clinical practice: opportunities and challenges. Proteomics Clin Appl 2013, 7:30-41.
• [6]Hynes RO: The extracellular matrix: not just pretty fibrils. Science 2009, 326:1216-1219.
• [7]Hynes RO, Naba A: Overview of the matrisome–an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol 2012, 4:a004903.
• [8]Cretu A, Brooks PC: Impact of the non-cellular tumor microenvironment on metastasis: potential therapeutic and imaging opportunities. J Cell Physiol 2007, 213:391-402.
• [9]Egeblad M, Nakasone ES, Werb Z: Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 2010, 18:884-901.
• [10]Lu P, Weaver VM, Werb Z: The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012, 196:395-406.
• [11]Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN, Tuveson DA: Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013, 62:112-120.
• [12]Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK: Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2011, 2:281-298.
• [13]Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, Hynes RO: The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics 2012, 11:M111.014647.
• [14]Naba A, Clauser KR, Lamar JM, Carr SA, Hynes RO: Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. eLife 2014, 3:e01308.
• [15]Naba A, Hoersch S, Hynes RO: Towards definition of an ECM parts list: an advance on GO categories. Matrix Biol 2012, 31:371-372.
• [16]Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
• [17]Del Rio M, Mollevi C, Vezzio-Vie N, Bibeau F, Ychou M, Martineau P: Specific extracellular matrix remodeling signature of colon hepatic metastases. PLoS One 2013, 8:e74599.
• [18]Ki DH, Jeung H-C, Park CH, Kang SH, Lee GY, Lee WS, Kim NK, Chung HC, Rha SY: Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer J Int Cancer 2007, 121:2005-2012.
• [19]Tsuji S, Midorikawa Y, Takahashi T, Yagi K, Takayama T, Yoshida K, Sugiyama Y, Aburatani H: Potential responders to FOLFOX therapy for colorectal cancer by random forests analysis. Br J Cancer 2012, 106:126-132.
• [20]Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, Paty PB, Gerald WL, Notterman DA, Domany E: Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A 2009, 106:7131-7136.
• [21]Lin AY, Chua M-S, Choi Y-L, Yeh W, Kim YH, Azzi R, Adams GA, Sainani K, van de Rijn M, So SK, Pollack JR: Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker. PLoS One 2011, 6:e16636.
• [22]Ben Q-W, Zhao Z, Ge S-F, Zhou J, Yuan F, Yuan Y-Z: Circulating levels of periostin may help identify patients with more aggressive colorectal cancer. Int J Oncol 2009, 34:821-828.
• [23]Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang X-F: Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004, 5:329-339.
• [24]Chlenski A, Cohn SL: Modulation of matrix remodeling by SPARC in neoplastic progression. Semin Cell Dev Biol 2010, 21:55-65.
• [25]Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P, Bulbule A, Kale S, Kumar S, Mishra R, Raja R, Saraswati S, Kaur R, Soundararajan G, Kumar D, Thorat D, Sanyal M, Ramdasi A, Ghosh P, Kundu GC: Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets 2011, 15:1113-1126.
• [26]Rangaswami H, Bulbule A, Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006, 16:79-87.
• [27]Liu AY, Zheng H, Ouyang G: Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol J Int Soc Matrix Biol 2014.
• [28]Yao L, Lao W, Zhang Y, Tang X, Hu X, He C, Hu X, Xu LX: Identification of EFEMP2 as a serum biomarker for the early detection of colorectal cancer with lectin affinity capture assisted secretome analysis of cultured fresh tissues. J Proteome Res 2012, 11:3281-3294.
• [29]Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, Sørensen S, Overgaard J, Lilja H, Harris A, Murphy G, Brünner N: Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002, 8:156-164.
• [30]Sørensen NM, Byström P, Christensen IJ, Berglund A, Nielsen HJ, Brünner N, Glimelius B: TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 2007, 13:4117-4122.
• [31]McPherson RA, Pincus MR: Henry’s Clinical Diagnosis and Management by Laboratory Methods. 22nd edition. Philadelphia, PA, U.S.A: Elsevier Health Sciences; 2011.
• [32]Pasche N, Neri D: Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012, 17:583-590.
• [33]Pasche N, Wulhfard S, Pretto F, Carugati E, Neri D: The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res 2012, 18:4092-4103.